ArticleScientific reports2025
The interference of baicalein with uric acid detected by the enzymatic method and its correction method.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of the interference of 49 commonly used clinical drugs on 60 biochemical tests.Practical laboratory medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the frequency of clinical application and international recognition of Chinese herbal medicines have been increasing, but the effect of Chinese herbal medicines on common clinical biochemical tests is still unclear. This study aimed to investigate the effect of baicalein, a Chinese herbal medicine ingredient, on uric acid (UA), cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol and to alleviate the interference of baicalein on these assays by improving the reagent. The interferences of baicalein during the detection of these five analytes were investigated on the Hitachi 7600 system. We prepared UA assay kit according to commercial standards to facilitate the improvement of the formulation and evaluated its performance. Tempol, which could eliminate the interference of baicalein, was found based on the chemical properties of the drug, and the optimum concentration for adding it to our UA reagent was determined. We found that the interference was concentration-dependent for five analytes, with the largest negative interference on UA determination. Self-prepared UA assay kit had a safe analysis performance. Our kit and the commercial kit showed a higher interference of - 71.75% and - 89.98% at 200 µg/mL baicalein, respectively. The addition of 5 mmol/L Tempol to the UA reagent could strongly resist the interference of baicalein. In Conclusion, baicalein has a negative interference effect on analysis based on the Trinder reaction, especially UA assay. With the increase in baicalein concentrations, the negative bias increased, and our improved UA reagent could resist the interference of baicalein on UA detection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.